June 16, 2017 / 11:00 AM / a month ago

BRIEF-Beigene presents initial phase 1 data on BTK inhibitor BGB-3111

1 Min Read

June 16 (Reuters) - Beigene Ltd

* Beigene presents initial phase 1 data on BTK inhibitor BGB-3111 combined with Obinutuzumab at the 14th international conference on malignant lymphoma and announces additional planned global registrational trials for BGB-3111

* ‍Only one patient discontinued treatment due to an AE, squamous cell carcinoma (SCC), and this patient had a prior history of SCC​

* Initial phase 1 data demonstrate that combination is well tolerated Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below